Gsk (GSK) Equity Average (2016 - 2025)
Gsk (GSK) posted Equity Average of $19.7 billion for Q4 2025, up 15.3% on a QoQ basis from $17.1 billion in Q4 2024, and up 15.3% year-over-year from $17.1 billion in Q4 2024.
Gsk (GSK) has 10 years of Equity Average data on file, last reported at $19.7 billion in Q4 2025.
- In Q4 2025, Equity Average rose 15.3% year-over-year to $19.7 billion; the TTM figure through Dec 2025 stood at $19.7 billion (up 15.3% YoY), while the FY2025 annual figure was $19.7 billion, up 15.3% from the prior year.
- Equity Average rose to $19.7 billion in Q4 2025, from $17.1 billion in the prior quarter.
- Across five years, Equity Average topped out at $19.8 billion in Q4 2021 and bottomed at $14.5 billion in Q4 2023.
- A 5-year average of $17.5 billion and a median of $17.1 billion in 2024 frame the typical range for Equity Average.
- Annual changes were most pronounced in 2022 — Equity Average declined 17.27% — and 2024, when it climbed 17.64%.
- Year by year, Equity Average stood at $19.8 billion in 2021, then slipped by 17.27% to $16.4 billion in 2022, then retreated by 11.39% to $14.5 billion in 2023, then advanced by 17.64% to $17.1 billion in 2024, then increased by 15.3% to $19.7 billion in 2025.
- The last three Equity Average figures came in at $19.7 billion (Q4 2025), $17.1 billion (Q4 2024), and $14.5 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 19.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.67 Bn |
| Dec 31, 2024 | 17.06 Bn |
| Dec 31, 2023 | 14.50 Bn |
| Dec 31, 2022 | 16.36 Bn |
| Dec 31, 2021 | 19.78 Bn |
| Dec 31, 2020 | 16.96 Bn |
| Dec 31, 2019 | 9.76 Bn |
| Dec 31, 2018 | 4.75 Bn |
| Dec 31, 2017 | 5.40 Bn |
| Dec 31, 2016 | 9.82 Bn |